Drug reference
samidorphan
opioid receptor antagonist · Opioid antagonist
opioid receptor antagonistOpioid antagonist
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
C
FDA category + note
Mechanism
Samidorphan is a µ-opioid receptor antagonist and modest κ-opioid receptor partial agonist that blunts the endorphin signal that reinforces eating behavior.
Indications
Limit olanzapine-related weight gain (in combination with olanzapine)management of schizophrenia (in combination with olanzapine, to reduce weight gain)
Pharmacokinetics
Bioavailability
Improved oral bioavailability
Pregnancy & lactation
Pregnancy
C
Lactation
Not specified
Related guidelines
Ask House about samidorphan
Continue into a citation-backed clinical answer with the drug context already attached.
Textbook-sourced·Sources: Goodman & Gilman 14e·Updated: 2026-05-10